Innoviva Company Profile (NASDAQ:THRX)

About Innoviva (NASDAQ:THRX)

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:THRX
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $9.81
  • 200 Day Moving Avg: $11.67
  • 52 Week Range: $6.36 - $21.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.70
  • P/E Growth: 0.00
  • Net Margins: 60.02%
  • Return on Assets: 36.91%
  • Average Volume: 867,484 shs.

Frequently Asked Questions for Innoviva (NASDAQ:THRX)

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "THRX."

Who are some of Innoviva's key competitors?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:

  • William H. Waltrip, Independent Chairman of the Board
  • Eric D'Esparbes, Chief Financial Officer, Senior Vice President
  • Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer
  • Michael E. Faerm, Senior Vice President and Chief Business Officer
  • Michael W. Aguiar, President, Chief Executive Officer, Director
  • Barbara G. Duncan, Independent Director
  • Catherine J. Friedman, Independent Director
  • Patrick G. LePore, Independent Director
  • Paul A. Pepe, Independent Director

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of Innoviva stock can currently be purchased for approximately $9.81.

MarketBeat Community Rating for Innoviva (NASDAQ THRX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:THRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Innoviva (NASDAQ:THRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/2/2016Morgan StanleyReiterated RatingSell$7.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Innoviva (NASDAQ:THRX)
No earnings announcements for this company have been tracked by


Earnings Estimates for Innoviva (NASDAQ:THRX)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.30 EPS


Dividend History for Innoviva (NASDAQ:THRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Innoviva (NASDAQ:THRX)
No insider trades for this company have been tracked by


Headline Trends for Innoviva (NASDAQ:THRX)
Latest Headlines for Innoviva (NASDAQ:THRX)
DateHeadline logoInnoviva (THRX) Earning Positive Media Coverage, Report Shows - May 3 at 8:38 PM logoFavorable News Coverage Somewhat Unlikely to Impact Innoviva (THRX) Stock Price - April 27 at 7:48 PM logoInnoviva (THRX) Receives Media Sentiment Score of 0.31 - April 24 at 5:32 PM logoInnoviva (THRX) Earning Positive Media Coverage, Study Finds - April 17 at 4:39 PM logoSomewhat Positive News Coverage Very Unlikely to Impact Innoviva (THRX) Stock Price - April 14 at 4:53 PM logoCruise Ship Heading From Miami to Havana - May 2 at 5:29 AM logoBodies of elite climber, cameraman found in melting Himalayan glacier - May 2 at 5:29 AM logoParamedic Says 'Yes' to Cop's Proposal Caught on Dash Cam - May 1 at 7:12 PM logoPete Wilson of California Backs Ted Cruz and Warns of Donald Trump - April 30 at 11:42 PM logoRacist texts prompt anti-bias training for San Francisco police - April 30 at 6:34 PM logo'Fargo' Cast Celebrate With Emmy Voters - April 29 at 6:45 PM logoAuthorities say death at Apple headquarters was suicide - April 29 at 12:04 AM logoDespite Cruz pact, Indiana paper backs Kasich in bid to stop Trump - April 29 at 12:04 AM logoMissing Money, a Vicious Attack and Slow Healing for a Charity’s Leader - April 28 at 6:57 PM logoE-Cigarettes Can Help Smokers Quit, U.K. Doctors Say - April 28 at 6:57 PM logoInnoviva meets 1Q profit forecasts - April 28 at 5:25 PM logoThe 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results - January 29 at 2:02 PM logoTheravance, Inc. Announces Name Change to Innoviva, Inc. - January 8 at 8:00 AM logoWill 2016 Be GlaxoSmithKline plc's Best Year Yet? - January 4 at 9:59 AM logoThe Best GlaxoSmithKline plc Headlines in 2015 - December 28 at 2:34 PM



Innoviva (THRX) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff